Myocardial Infarction in the Young: A Prospective Clinical Registry Study

Western Sydney Local Health District0 个研究点目标入组 500 人开始时间: 2023年12月7日最近更新: 2023年12月12日

适应症

试验速览

暂无简介。

•Patients aged =>18 years and <50 years old with acute myocardial infarction (MI)
•Type 1 and Type 2 MI are both included, with MI defined according to the 4th universal definition.
•Clinical evidence of acute myocardial ischaemia and detection of a rise and/or fall of cTroponin values with at least 1 value above the 99th percentile upper reference limit and, at least one of the following:
•1. Symptoms of myocardial ischaemia;
•2. New ischaemic ECG changes;
•3. Development of pathological Q waves;
•4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology;
•5. Identification of a coronary thrombus by angiography or autopsy
•6. Patients must have undergone coronary angiography.
•7. Patients must be able to provide informed consent.

•Rise in cardiac biomarkers and/or ECG changes due to a clear non-coronary artery pathology e.g. myocarditis, acute arrhythmia, cardiomyopathy, acute pulmonary embolism (PE), stroke, recent cardiac surgery (these can all cause ischaemic changes on the ECG and/or troponin rises)
•Patients with presumed MI who die before the diagnosis has been confirmed by troponin values or coronary angiography (Type 3 MI)
•Percutaneous coronary intervention (PCI)-related MI (Type 4 MI)
•Coronary artery bypass grafting (CABG)-related MI (Type 5 MI)

发起方